Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elsa Quintana

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Science (New York, N.Y.)|March 12, 2026
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinomaMinh T Than, Lucie Dequiedt, Rina Sor, et al.
Cell Chemical Biology|August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancersWadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery|October 23, 2025
A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancerAlessia Centonze, Adrià-Jaume Roura, Meritxell Novillo-Font, et al.
Cancer Discovery|October 6, 2025
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|February 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint BlockadeXing Wei, Cristina Blaj, M Ali Al-Radhawi, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Science (New York, N.Y.)|March 12, 2026
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinomaMinh T Than, Lucie Dequiedt, Rina Sor, et al.
Cell Chemical Biology|August 13, 2025
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancersWadie D Mahauad-Fernandez, Yu Chi Yang, Ian Lai, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery|October 23, 2025
A plastic EMP1⁺ to LGR5⁺ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancerAlessia Centonze, Adrià-Jaume Roura, Meritxell Novillo-Font, et al.
Cancer Discovery|October 6, 2025
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|February 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint BlockadeXing Wei, Cristina Blaj, M Ali Al-Radhawi, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 4